Indication
Inflammatory Breast Cancer Stage III
1 clinical trial
1 product
1 drug
Clinical trial
TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast CancerStatus: Recruiting, Estimated PCD: 2027-12-01
Product
DurvalumabDrug
Trastuzumab